Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Summary
- As early as week 6 of treatment, relacorilant resulted in clinically and statistically significant improvement in blood pressure in patients with endogenous hypercortisolism and hypertension
- This early hypertension control with relacorilant was maintained throughout the GRACE OL and RW phases and long-term treatment through month 12 of the OLE
- In the GRACE OL phase, relacorilant treatment significantly improved the weight gain often observed in patients with endogenous hypercortisolism, and this trend continued in the OLE
- Relacorilant significantly reduced HbA1c during the GRACE OL phase, and this trend continued during the OLE study